New drug GenSci155 enters first human safety tests
NCT ID NCT07638800
First seen Jun 12, 2026 · Last updated Jun 15, 2026 · Updated 1 time
Summary
This early-stage study tests the safety of a new drug called GenSci155 in 68 healthy adults aged 18 to 60. Participants receive either the drug or a placebo by IV, and researchers monitor for side effects and how the drug moves through the body. The goal is to gather safety and dosing information, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT TRIAL PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070, China
Conditions
Explore the condition pages connected to this study.